Extension of Option Exercise Period
Scancell Holdings plc announced an extension of the exercise period for 3.85 million share options awarded to its Chief Scientific Officer, Lindy Durrant, from July 30, 2026, to January 31, 2027, with an exercise price of 4.5 pence per share. This extension is considered a related party transaction, and the independent Directors, in consultation with the Company's nominated adviser, deem it fair and reasonable for shareholders.
Select text to share a quote on X · sign in to keep highlights & notes in your SCLP notes
Scancell (AIM: SCLP), the developer of active immunotherapies to treat cancer, announces that the exercise period for 3.85 million share options awarded to Lindy Durrant, Chief Scientific Officer of the Company, on 30 July 2020 has been extended from 30 July 2026 to 31 January 2027.
These options have an exercise price of 4.5 pence each. All other conditions of the award remain the same.
The extension of the expiry date for the share options amounts to a related party transaction within the meaning of the AIM Rules for Companies. The Directors who are independent of the related party transaction (being all the Directors of the Company other than Lindy Durrant) having consulted with Panmure Liberum, the Company's nominated adviser, consider this proposed extension of the expiry date to be fair and reasonable insofar as the shareholders of the Company are concerned.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.